ADVB Advanced Biomed Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1941029 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY279.7%
TTM EPS YoY244.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE85.0%
ROA63.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets12.5%
Debt / equity0.00x
Current ratio8.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.25x
Accruals ratio79.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 |
|---|---|---|---|
| Income statement | |||
| Revenue | $127,637 | — | — |
| R&D expense | — | $909,771 | $880,193 |
| SG&A expense | $4.63M | $1.09M | $1.66M |
| Operating income | -$6.23M | -$1.09M | — |
| Pretax income | -$6.26M | -$1.09M | -$2.78M |
| Income tax | -$1,205 | — | — |
| Net income | $6.68M | -$3.26M | -$2.78M |
| EBITDA | — | -$742,640 | — |
| EPS (basic) | 5.33 | -3.18 | -0.14 |
| EPS (diluted) | 5.33 | -3.18 | -0.14 |
| Weighted avg. shares (diluted) | 1.25M | 1.03M | 20.00M |
| Balance sheet | |||
| Cash & equivalents | $385,535 | $31,139 | $2.61M |
| Current assets | $13.75M | $22.38M | $3.05M |
| PP&E, net | — | $125,184 | $524,528 |
| Intangibles | — | — | $118,998 |
| Total assets | $13.75M | $22.86M | $4.46M |
| Current liabilities | $1.47M | $19.24M | $2.73M |
| Total liabilities | $1.47M | $19.38M | $2.80M |
| Shareholders' equity | $12.28M | $3.48M | $1.66M |
| Shares outstanding | 1.65M | 1.08M | 20.00M |
| Cash flow statement | |||
| Operating cash flow | -$1.95M | -$5.83M | -$2.13M |
| Capital expenditure | — | $31,650 | $74,110 |
| Free cash flow | — | -$5.86M | -$2.20M |
| Investing cash flow | -$2.51M | -$31,650 | -$74,110 |
| Financing cash flow | $1.97M | $5.93M | $1.87M |
| Depreciation & amortization | — | $343,830 | $399,602 |
| Stock-based compensation | $1.73M | — | — |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.